Everence Capital Management Inc. Has $4.28 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Everence Capital Management Inc. increased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 20.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 83,350 shares of the biopharmaceutical company’s stock after buying an additional 14,424 shares during the quarter. Everence Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $4,277,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Herold Advisors Inc. boosted its holdings in Bristol-Myers Squibb by 3.2% during the third quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company’s stock valued at $1,954,000 after purchasing an additional 1,051 shares in the last quarter. Kestra Private Wealth Services LLC raised its stake in shares of Bristol-Myers Squibb by 9.5% in the third quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company’s stock valued at $8,115,000 after acquiring an additional 12,121 shares during the last quarter. Metis Global Partners LLC raised its stake in shares of Bristol-Myers Squibb by 14.8% in the third quarter. Metis Global Partners LLC now owns 101,772 shares of the biopharmaceutical company’s stock valued at $5,907,000 after acquiring an additional 13,122 shares during the last quarter. Jmac Enterprises LLC raised its position in Bristol-Myers Squibb by 11.4% in the 3rd quarter. Jmac Enterprises LLC now owns 12,171 shares of the biopharmaceutical company’s stock worth $706,000 after purchasing an additional 1,245 shares during the last quarter. Finally, Vontobel Holding Ltd. raised its position in Bristol-Myers Squibb by 17.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 3,653,151 shares of the biopharmaceutical company’s stock worth $212,029,000 after purchasing an additional 530,405 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Down 0.5 %

NYSE:BMY traded down $0.25 on Tuesday, hitting $48.26. 11,918,645 shares of the company’s stock were exchanged, compared to its average volume of 15,903,306. The firm has a 50-day moving average price of $51.29 and a 200-day moving average price of $51.69. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. Bristol-Myers Squibb has a 52 week low of $47.58 and a 52 week high of $70.93. The company has a market cap of $97.81 billion, a P/E ratio of 12.56, a price-to-earnings-growth ratio of 1.78 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The company had revenue of $11.48 billion for the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. Bristol-Myers Squibb’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.82 EPS. As a group, analysts expect that Bristol-Myers Squibb will post 5.41 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.97%. Bristol-Myers Squibb’s payout ratio is 62.18%.

Analyst Ratings Changes

Several research firms recently weighed in on BMY. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Wells Fargo & Company dropped their target price on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 6th. Finally, Bank of America cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the company from $68.00 to $60.00 in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $61.12.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.